Delivered as a 12-month subcutaneous implant for continuous GnRH receptor activation.
Also known as: Supprelin LA · Vantas · GnRH agonist
Part of the Foundational & therapeutic peptides cluster
Overview
Histrelin is a synthetic GnRH agonist peptide administered as a subcutaneous implant that releases drug continuously over about a year. It is an approved prescription medicine for central precocious puberty in children and for hormone-sensitive prostate cancer in adults. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic GnRH analog
Primary research or clinical context: Approved medicine for central precocious puberty and hormone-sensitive prostate cancer, delivered by subcutaneous implant (prescription)
Implant delivery
Rather than repeated injections, histrelin is placed in a small hydrogel implant under the skin of the upper arm. Continuous release maintains receptor desensitization, suppressing gonadotropins and sex hormones until the implant is removed or replaced.
Peptide design
Histrelin is a nonapeptide GnRH analog with a D-histidine substitution and an ethylamide C-terminus. These modifications increase potency and metabolic stability relative to native GnRH, supporting the long-duration implant format.
FAQ about Histrelin
What is Histrelin?+
Histrelin is a synthetic GnRH agonist peptide administered as a subcutaneous implant that releases drug continuously over about a year. It is an approved prescription medicine for central precocious puberty in children and for hormone-sensitive prostate cancer in adults. This page is educational and is not medical advice.
Is Histrelin an approved medicine?+
Histrelin: Approved medicine for central precocious puberty and hormone-sensitive prostate cancer, delivered by subcutaneous implant (prescription). Always follow licensed medical guidance for approved products.
What is the typical length of Histrelin?+
Histrelin is commonly described as approximately 9 amino acids (GnRH agonist (nonapeptide analog)).